Novartis announces positive results from asthma combinations

Novartis has announced positive results from trials testing its daily fixed dose treatment two-drug combination for people with uncontrolled asthma, QMF149, and its triple combination QVM14

Device advancements to be discussed at the Respiratory Drug ...

Device advancements to be discussed

Key Opinion Leaders to present at the Respiratory Drug Deliv...

Respiratory Drug Delivery

EU clears GSK’s asthma drug Nucala in patient-friendly forma...

Boehringer announces IPF deal with Korea's Bridge Biotherape...

Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).

Three Interactive Sessions to take place at the Respiratory ...

Interactive Sessions at RDD